A step forward, but not the finish line: What NICE’s QALY up...
Healthcare in the UK is at an inflection point.
Newsletters and Deep Dive digital magazine
Healthcare in the UK is at an inflection point.
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Editor's Picks
Newsletters and Deep Dive
digital magazine